Literature DB >> 12640290

Polycythemia vera responds to imatinib mesylate.

C Michael Jones1, Tina Marie Dickinson.   

Abstract

We report 2 patients with polycythemia vera who were demonstrated to be -negative and were unable to tolerate either hydroxyurea or interferon-alpha but who had excellent clinical responses to imatinib mesylate (STI-571). This effect is consistent with the inhibitory effect of imatinib mesylate on c-kit's tyrosine kinase activity as demonstrated by its effectiveness in patients with gastrointestinal stromal tumors.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12640290     DOI： 10.1097/00000441-200303000-00007

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN： 0002-9629            Impact factor:   2.378


  9 in total

1.  Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors:  Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

2.  Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.

Authors:  Roberto H Nussenzveig; Jorge Cortes; Matjaz Sever; Alfonso Quintás-Cardama; Pat Ault; Taghi Manshouri; Carlos Bueso-Ramos; Josef T Prchal; Hagop Kantarjian; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2009-05-30       Impact factor: 2.490

Review 3.  Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

Authors:  Srdan Verstovsek
Journal:  Leuk Res       Date:  2008-11-14       Impact factor: 3.156

4.  Use and risks of phosphorus-32 in the treatment of polycythaemia vera.

Authors:  Claude Parmentier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-03       Impact factor: 9.236

5.  Phase II open label trial of imatinib in polycythemia rubra vera.

Authors:  C Michael Jones; Tina M Dickinson; August Salvado
Journal:  Int J Hematol       Date:  2008-11-15       Impact factor: 2.490

Review 6.  Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Authors:  Richard T Silver
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

7.  In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow.

Authors:  P B Soares; T S Jeremias; M Alvarez-Silva; M A Licinio; M C Santos-Silva; C L Vituri
Journal:  Braz J Med Biol Res       Date:  2012-09-25       Impact factor: 2.590

Review 8.  Cancer treatment with kinase inhibitors: what have we learnt from imatinib?

Authors:  D M Ross; T P Hughes
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

9.  Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.

Authors:  Amos Gaikwad; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.